Lula Government Faces Scrutiny Over Insulin Contracts to Biomm Linked to Banker Under Investigation
By Hotspotnews
In a story that has reignited political tensions in Brazil, the administration of President Luiz Inácio Lula da Silva is under fire for awarding more than 300 million reais in public contracts to biotech firm Biomm for the supply of insulin to the country’s public health system. Critics allege the deals smack of favoritism, pointing to the company’s major shareholder ties to banker Daniel Vorcaro and a private meeting between Lula and Vorcaro that occurred off the official presidential agenda.
The contracts, signed throughout 2025, involve the production and delivery of human insulin and glargine insulin for the Sistema Único de Saúde (SUS). According to company disclosures and government records, the agreements total at least 303 million reais and were structured through public-private partnerships known as Parcerias para o Desenvolvimento Produtivo (PDPs), as well as electronic auctions. These deals aim to bolster domestic production of essential medicines, reducing Brazil’s long-standing reliance on imported insulin.
Biomm, a publicly traded company listed on the Brazilian stock exchange, has positioned the contracts as a milestone for national self-sufficiency in biotechnology. The firm has emphasized that the procurement followed standard bidding procedures, with Biomm emerging as the lowest bidder in competitive processes. Deliveries have reportedly met quality and volume targets, supporting millions of SUS patients who depend on affordable insulin for diabetes treatment.
At the center of the controversy is Daniel Vorcaro, founder of Banco Master. Through an investment fund connected to the bank, Vorcaro holds a significant stake in Biomm—reportedly around 26 percent—making him one of the company’s largest individual shareholders. Other notable investors include former government officials. The timing has raised red flags: Vorcaro met privately with Lula at the Planalto Palace in December 2024, alongside figures such as then-nominated Central Bank president Gabriel Galípolo and ministers. The encounter, which was not listed on the official presidential schedule, was later acknowledged by Lula himself. He described it as informal and insisted there was no interference in ongoing Central Bank matters involving Vorcaro’s bank.
That bank, Banco Master, collapsed in late 2025 amid allegations of fraud and liquidity crises involving billions of reais. The Central Bank ordered its liquidation as part of broader investigations, including Operation Compliance Zero. Opposition lawmakers have seized on the sequence of events—factory inaugurations attended by Lula in 2024, the private meeting, the 2025 contracts, and the bank’s downfall—as evidence of cronyism. Calls for a congressional inquiry commission (CPMI) into Banco Master have intensified, with Biomm’s dealings frequently cited as part of the narrative.
Further fueling the debate is the involvement of Márcio Pochmann, president of the Brazilian Institute of Geography and Statistics (IBGE). Pochmann served on Biomm’s board of directors from April 2024 until April 2026, a period that overlapped with his government role. Critics, including deputies from opposition parties, have filed formal complaints alleging a conflict of interest, arguing that access to sensitive public data could have indirectly benefited the company.
Government officials and Biomm representatives defend the arrangements as fully transparent and compliant with Brazilian law. They note that the PDP framework for insulin production was originally conceived years earlier—under previous administrations dating back to 2013—and restarted in 2023 to address strategic health needs. The Ministry of Health maintains that electronic auctions and partnership rules ensured competition and value for taxpayers. Supporters argue the focus on local production is a legitimate public policy success, not political favoritism, and that shareholder investments do not equate to operational control.
Yet the optics remain troubling for many observers. Public contracting in Brazil’s health sector has long drawn criticism from the Federal Court of Accounts (TCU) for issues like limited competition and higher costs in similar partnerships. In this case, additional public financing—reportedly including loans and grants from development banks like BNDES and Finep—has pushed the total support for Biomm well beyond the insulin contracts, exceeding 600 million reais according to some estimates. While such funding is common for biotech development, the combination of high-level political access and the beneficiary’s profile has amplified perceptions of undue influence.
The episode underscores a familiar pattern in Brazilian politics: accusations of “apadrinhamento,” or sponsorship of connected interests, fly regardless of which party holds power. What began as routine procurement for life-saving medication has become ammunition in the ongoing ideological battles ahead of future elections. As investigations into Banco Master continue and potential audits loom, more details could emerge about the extent of any coordination or irregularities.
For now, no court or oversight body has invalidated the Biomm contracts. The government insists the deals deliver real benefits to Brazilian patients, while critics maintain that true transparency requires more than procedural compliance—it demands distance from private interests entangled in scandal. In the court of public opinion, the jury remains out, and the story is far from over.